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The effect on liver and heart allograft survival (ACI 
rats to Lewis rats) was studied after three methods of 
recipient presensitization and after different intervals 
between sensitization and transplantation. With com-
parable lymphocytotoxic antibody titers, liver al-
lografts always survived longer than heart grafts. The 
titer, class and specificity of the antibodies varied with 
the method of sensitization. Four skin grafts produced 
IgG and IgM lymphocytotoxic antibody titers of 1 : 2,000 
to 4,000. The IgG fraction was shown to have hepatic 
vascular endothelial specificity by indirect immunoflu-
orescence. These primed recipients hyperacutely re-
jected both heart and liver allografts, which showed 
vascular deposition of IgG antibodies. Survival of 
either kind of graft was inversely proportional to the 
Iymphocytotoxic antibody titer and length of time 
after placement of the last skin graft. Presensitization 
with a single heterotopic heart graft produced an even 
higher mixed IgG and IgM lymphocytotoxic antibody 
titer of 1: 8,000 but with less IgG vascular endothelial 
specificity. These animals also hyperacutely rejected 
heart or liver grafts with tissue deposition of IgG but 
less consistently and with a weaker correlation with 
lymphocytotoxic antibody titers and time after sensi· 
tization. Sensitization with two pretransplant blood 
transfusions produced the lowest titer (1: 500 to 1,000) 
and the least IgG vascular endothelial specificity. Liver 
allograft survival was routinely enhanced in these 
animals, and little effect was seen on heart grafts. 
Collectively, the experiments showed that the liver is 
not only resistant to antibody-mediated rejection rel-
ative to the heart but is more easily enhanced. A more 
precise characterization of preformed antibodies may 
increase the ability to predict the outcome of liver 
transplantation in sensitized recipients or guide pre-
transplant strategies to foster enhancing antibodies. 
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The relationship between preformed complement-
fixing lymphocytotoxic antibodies (LAbs) and rapid 
kidney allograft rejection is well known (1, 2). However, 
liver allografts are relatively resistant to preformed 
LAbs; hyperacute rejection is rarely observed in clinical 
practice (3, 4) and is difficult to produce in experimental 
animal models (6, 6). The liver's resistance is thought to 
be caused by many factors, but recent clinical evidence 
and studies of highly sensitized animal models have 
shown that this privileged state is only relative (4-10). 
Because of conflicting results in clinical practice with 
sensitized liver allograft recipients (3-4, 7-10), the 
practical significance of LAbs in an individual patient 
and whether they should interdict candidacy is difficult 
to judge. 
In an attempt to learn more about the interactions 
between preformed LAbs and liver allografts, we sensi-
tized rats with heart, skin or whole blood and varied the 
time between the last priming and placement of the test 
heart or liver allograft. 
MATERIALS AND METHODS 
Animals 
Male inbred Lewis (LEW, RT1!) rats weighing 180 to 250 
gm and ACI (RTI B) rats weighing 180 to 300 gm (Harlan 
Sprague Dawley Inc., Indianapolis, IN) were used as recipients 
and donors, respectively. The animals were housed in conven-
tional facilities with water and commercial rat chow provided 
ad libitum. 
Sensitization Protocols 
Skin Grafting. LEW recipients were sensitized with four 
successive skin grafts using a modification of the method 
described by Guttmann (11). Full thickness ACI tail skin grafts 
(2 cm in diameter) were sutured to the flank. of LEW recipients 
with 4-0 Novafil (Davis and Geck, Inc. Manati, PR), and a 
plaster bandage was applied for 5 days. The procedure was 
repeated three more times at 14-day intervals. 
Heart Grafting. ACI heterotopic heart grafts were anasto-
mosed to the infrarenal abdominal aorta and vena cava of LEW 
recipients as described by Ono and Lindsey (12). The grafts 
were palpated daily until the heartbeat ceased, which uni-
formly occurred on the sixth or seventh day. 
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Whole-blood Transfusions. One milliliter of heparinized 
ACI whole blood was given intravenously to LEW recipients on 
two different occasions at a 7 -day interval. 
Experimental Design 
Operative Methods. Heart grafts were placed in the neck of 
LEW recipients using the method of Heron (13). The graft 
aorta and pulmonary artery were connected to the carotid 
artery and jugular vein of the recipient, respectively. The heart 
grafts were directly monitored for the first 30 min, palpated 
through the skin each hour for the first 6 hr and every 12 hr 
thereafter. Graft rejection was diagnosed when no palpable 
contractions were observed; it was confirmed by direct in-
spection and histological examination. 
The orthotopic liver transplant procedure used the cuff 
technique for the portal and infrahepatic vena cava anasto-
moses, according to the method of Kamada and Calne (14). 
Arterial reconstruction was omitted because in pilot experi-
ments many grafts were destroyed or gravely damaged by 
accelerated rejection between the time of portal revascular-
ization and completion of the arterial anastomosis. Graft 
rejection was diagnosed by the death of the animals and 
confirmed by histological examination. 
Timing of Test Grafting. ACI heart or liver grafts were 
placed into LEW recipients at 2, 4, 6, 9, 12 and 15 wk after 
completion of the skin and heart sensitization protocols. Heart 
or liver transplantation was completed 1 wk after the second 
blood transfusion. Six or seven experiments were performed at 
each time point. 
Lymphocytotoxic Activity and Flow 
Cytometric Analysis 
Serum samples for antibody analysis were obtained imme-
diately before transplantation and at the time of graft 
rejection. Samples were stored at - 70° C until the cytotoxic 
crossmatch, flow cytometric analysis or indirect immunofluo-
rescent assays were performed. 
A complement-fixing LAb assay was performed with unfrac-
tionated donor ACI lymphocytes and immune LEW sera 
according to the method of Terasaki et al.(15). Serum samples 
were serially diluted from 1: 1 to 1: 2 (16) with RPMI 1640 
(Gibco, Grand Island, NY) supplemented with 25 mmol/L 
HEPES buffer (Gibco), 1.6 mmol/L L-glutamine (Gibco), 50 
f.lg/ml gentamicin (Gibco) and 10% heat-inactivated normal rat 
serum. Cell lysis was scored as follows: 0 = undetectable, 
1 = 0% to 10%;2 = 11% to 20%; 4 = 21%t050%;6 = 51%to 
80%; 8 = 81% to 100%. All samples were run in duplicate. The 
LAb titer was defined as the most dilute serum sample with a 
score greater than 6 (greater than 50% cell lysis). 
ACI peripheral lymph node cells (5 x 105 ) were used as 
targets for flow cytometric analysis; the phenotypic compo-
sition was determined using OX19 (T cells; Accurate Chemical 
and Scientific Corp., Westbury, NY), OX33 (B cells, Accurate 
Chemical and Scientific Corp.) and goat antirat IgG or IgM (B 
cells; Accurate Chemical and Scientific Corp.). Target lym-
phocyte phenotype was determined by incubation of the target 
lymphocytes with the primary antibody (OX19 or OX33) for 45 
min, followed by two washes and labeling with FITC-
conjugated goat antimouse immunoglobulin (Accurate 
Chemical and Scientific Corp.). The percentage of B cells 
(OX33 + or IgG and IgM + ) varied between 30% to 38%, with 
T cells (OX19+) comprising most (65% to 75%) of the 
remaining population. 
For ACI lymphocyte binding activity of the immune sera and 
determination of titers, diluted immune LEW serum samples 
(1: 10, 1: 100, 1: 500 and 1: 1,000 in HBSS with 1% BSA and 
0.1 % NaNa) were incubated with the targets for 45 min at 
4° C. Nonimmune LEW sera served as a control. After 
incubation, cells were washed and FITC-conjugated goat 
antirat IgG (Accurate Chemical and Scientific Corp.) or IgM 
antibody (1 : 75 dilution) was added and incubated for another 
30 min at 4°C. Cells were then washed twice and fixed in 1% 
paraformaldehyde. 
Samples were analyzed by FASTAR (Becton Dickinson & 
Co., Franklin Lakes, NJ). A total of 5,000 cells were analyzed, 
and the fluorescent profiles of the ACI cells after labeling with 
immune serum samples were compared with the profiles 
obtained after labeling with normal LEW serum and after 
OX19, OX33, IgM or IgG labeling. The percentage of positive 
cells and the phenotype of the targets was determined by 
subtraction from the normal control background. 
Routine and Immunopathological Studies 
Failed allograft tissues were processed for routine patho-
logical analysis, and a portion was frozen for direct immuno-
fluorescent studies. A diagnosis of pure humoral rejection of 
the heart or liver was made when histological examination of 
the grafts revealed hemorrhagic necrosis, with platelet/fibrin 
thrombi and neutrophils in the microvasculature but without 
a significant mononuclear inflammatory infiltrate. Mixed 
humoral and cellular rejection was diagnosed when the above 
findings were found in conjunction with a predominantly 
mononuclear graft infiltrate combined with tissue deposition 
of IgG. 
Direct immunofluorescence studies on failed allografts were 
performed in representative animals from each group, using 
goat antirat IgG and IgM (Accurate Chemical and Scientific 
Corp.) to detect immunoglobulin deposits. Indirect immuno-
fluorescent studies were used to detect the target antigen 
specificity, class and intensity of binding of the LEW immune 
sera in the ACI liver. Normal frozen ACI liver sections (2 f.lm) 
were blocked with protein-blocking agent for 30 min, blotted 
and then overlaid with undiluted immune LEW serum for 45 
min. The slides were then washed two times and incubated 
with goat antirat IgG or IgM for 30 min, washed two times and 
evaluated on a fluorescent microscope. Nonimmune LEW sera 
served as a control. All of the pathological analyses were 
performed without knowledge of the type of sensitization or 
primary immunoreactant (blinded review). 
Statistical Analysis 
All results were analyzed for statistical significance by the 
Mann-Whitney U test, except for the results of changes in 
antibody titer before and after transplantation, which were 
analyzed by the Wilcoxon signed rank test. The differences 
were considered statistically significant if p < 0.01. 
RESULTS 
Lymphocytotoxic Antibody Titer, Class and Specificity 
After Sensitization 
Both routine cytotoxic and flow cytometric cross-
matches were negative using nonimmune LEW sera. 
However, all three sensitization protocols produced 
antibodies cytotoxic to ACI lymphocytes. The highest 
titers were observed during the first 6 wk after heart 
(1: 8,000) and the final skin (1: 2,000 to 4,000) sensiti-
zation (Fig. 1). Antibody titers after whole-blood sensi-
tization were only measured 1 and 2 wk after the last 
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FIG. 1. The changes in LAb titer after sensitization (mean ± S.D.). 
Titers more than 9 wk after heart sensitization and more than 15 wk 
after skin sensitization were significantly different than initial titers 
at 2 wk (*p < 0.01). In addition, titers less than 6 wk after heart 
sensitization and 4 wk after skin sensitization were significantly 
higher than after blood sensitization (**p < 0.01). 
transfusion and were lower (1: 500-1,000). The speci-
ficity of the cytotoxic antibodies as defined by flow 
cytometry and indirect immunofluorescence is given 
below. 
Skin Sensitization. Two weeks after concluding the 
sensitization, flow cytometry revealed that skin priming 
produced immune sera containing both IgG and IgM 
antibodies, both of which reacted with more than 90% 
of ACI cells, which contained both T and B cells. Dilu-
tional analysis revealed that the IgG fraction was 
present in higher concentration than IgM (> 1: 1,000 
vs. < 1:500). 
Indirect immunofluorescent studies using 2-wk 
immune LEW sera revealed intense linear IgG > > IgM 
reactivity with all endothelia, bile duct epithelia and 
weaker hepatocyte staining (Table 1). 
Heart Sensitization. After heart sensitization, flow 
cytometric studies revealed IgG and IgM antibodies 
(both > 1: 1,000) and binding with more than 90% of 
ACI lymphocytes, which contained both T and B cells. 
However, despite the higher titers, less intense hepatic 
endothelial IgG reactivity by indirect immunofluores-
cence was seen (Table 1). IgM localization revealed a 
distinctly granular pattern in sinusoidal cells and on 
hepatocytes. 
Blood Sensitization. Cytotoxic antibody titers after 
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FIG. 2. Graft survival time after skin sensitization. Heart or liver 
grafts surviving more than 3 days showed a mixed humoral and 
cellular rejection (open circles), whereas those failing before 3 days 
showed more humoral rejection (closed circles). *Median survival time 
of ACI heart graft (6 days, N = 7). **Median survival time of ACI liver 
graft (10 days, N = 7) in unsensitized LEW recipients. 
1,000; P < 0.01) than either heart or skin. By flow 
cytometry the concentration of IgG equaled IgM « 1: 
1,000), and both T-cell and B-ceU binding were observed. 
However, by indirect immunofluorescence the l-wk 
antiserum reacted only weakly with hematolymphoid 
cells amid the portal connective tissue for both IgG and 
IgM (Table 1). The larger vessel endothelium was only 
weakly or equivocally positive. Sera obtained after 2 wk 
showed slight increases for both IgG and IgM, but the 
binding did not approach that seen with 2-wk heart or 
skin sera. 
Evolution of Antibody Titer, Class and Specificity 
Sequential analysis of the cytotoxic activity of the 
immune sera revealed a gradual decline in antibody titer 
between 6 and 15 wk after both heart and skin 
sensitization (Fig. 1). Compared with levels at 2 wk, the 
decline became statistically significant by 9 wk for heart 
priming and by 15 wk for skin immunization. 
The decrease in IgG and IgM titers was also noted by 
flow cytometry dilutional analysis and by a shift to a 
lower channel for both IgG and IgM. For the skin-
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FlG. 3. Correlation between heart or liver graft survival and LAb titer after skin or heart sensitization. Skin/heart = heart graft survival and 
cytotoxic antibody titer after skin sensitization. Regression equation: log10 (Y) = 3.5713 - 0.41796X, r = 0.6766, p < 0.01. Skinlliver = liver 
graft survival and cytotoxic antibody titer after skin sensitization. Regression equation: loglO (Y) = 1.9549 - 0.15054X, r = 0.5690, p < 0.01. 
Heart/heart = heart graft survival and cytotoxic antibody titer after heart sensitization. Regression equation: log10 (Y) = 2.3070 - 0.18928X, 
r = 0.5042, p < 0.01. Heartlliver = liver graft survival and cytotoxic antibody titer after heart sensitization. Regression equation: loglO 
(y) = 1.1692 - 0.071396X, r = 0.2811; NS. 
TABLE 1. Hepatic specificity analysis of preformed antibodies by indirect immunofluorescence" 
Method of Time 
sensitization (wk) PV IIA BD HLC SIN CV 
Skin 2 3/2 3/2 3/1 3/1 3/2b 3/2 
15 2/0 2/0 I/O 1/0 2/2b 2/0 
Heart 2 2/1 2/0 1/1 2/2 2/2b 2/1 
15 1/± 2c/0 1/1 2/2 1/1b 1/1 
Blood 1 ±/1 0/0 ±/1 1/1 ±b/1b 0/0 
2 1/1 1/1 2/1 1/1 2b/2b 0/1 
PV = portal vein; HA = hepatic artery; BD = bile duct; HLC = portal tract hematolymphoid cells; SIN = sinusoids; CV = central vein. 
The indirect immunofluorescence was scored subjectively on a scale from 0 to 3, with 0 = negative and 3 = strongly positive. 
aThe fluorescent intensity of IgG deposits/IgM deposits. 
bSinusoidal binding was distinctly granular. 
CReactivity with arterial smooth muscle cells. 
sensitized rats, overall titers were lower but the ratio of 
IgG/lgM did not change. However, immune sera pro-
duced by heart priming at 15 wk showed a shift to an 
IgG-predominant response (> 1: 1,000) compared with 
IgM « 1:500). 
Indirect immunofluorescence of immune sera 15 wk 
after heart or skin sensitization revealed a decreased 
binding, which was greater for IgM than IgG compared 
with 2-wk sera. No appreciable change in tissue speci-
ficity was detected for skin-primed rats. However, 
heart-sensitized immune sera demonstrated a greater 
predilection for portal tract structures, including vas-
cular smooth muscle cells, than did similar sera obtained 
after 2 wk (Table 1). 
Graft Survival as a Function of Postsensitization 
Time and Antibody Titers 
Skin Sensitization. Survival of heart and liver grafts 
as a function of the time after sensitization is shown in 
Figure 2. If the heart grafts were placed less than 10 wk 
after the last skin transplant, they always were hyper-
acutely rejected. Typically, these heart grafts became 
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cyanotic, edematous and hemorrhagic within a few 
minutes after adequate revascularization. Microscopic 
examination revealed classic hyperacute rejection with 
vascular deposition of IgG. 
If heart placement was delayed until 12 to 15 wk, an 
accelerated mixed humoral and cellular rejection was 
nearly as common as pure humoral or hyperacute 
rejection. Heart grafts survived significantly longer 
when placed after 12 wk (mean survival = 43.7 hr; 
median = 18.8 hr) compared with heart transplants 
completed before 10 wk (mean survival = 1.7 hr; medi-
an = 0.9 hr; p < 0.01). In addition, a strong inverse 
correlation was seen between LAb titers and heart graft 
survival (Fig. 3). 
Liver allografts always survived longer than heart 
grafts placed after skin sensitization (Fig. 2). During the 
first 6 wk after sensitization, all livers were rejected 
within 3 days. Characteristically, the hepatic grafts 
became mottled and pale soon after portal revascular-
ization. This was accompanied by severe portal hyper-
tension and mesenteric congestion. During the next 24 
hr, the portal hypertension waned, the livers became 
small and pale and the recipient became anemic and had 
copious thin bloody ascites develop. Pathologically, 
characteristic findings included marked platelet 
plugging of the vasculature, congestion, maplike areas of 
coagulative necrosis and diffuse vascular deposition of 
IgG alone. 
If liver placement was delayed for more than 9 wk, a 
range of graft survivals was observed, some of which 
approached unsensitized controls (Fig. 2). Pathologi-
cally, the failed grafts showed a mixed humoral and 
cellular rejection characterized by a mixed cellular portal 
infiltrate, platelet plugs, infarcts and focal sinusoidal 
IgG deposits. An inverse relationship between antibody 
titers and liver graft survival was seen (Fig. 3), but this 
was less strong than when the heart was the test graft. 
Heart Sensitization. Heart and liver graft survival in 
LEW recipients presensitized with ACI heart grafts was 
more variable than after skin priming (Fig. 4), although 
the trends after heart priming were the same. In 
addition, a less strong correlation was seen with LAb 
titers (Fig. 3), which were actually higher than after skin 
sensitization. 
Most heart grafts placed during the first 6 wk were 
hyperacutely rejected, but with a delay of more than 9 
wk median survival was between 50 and 60 hr. Most of 
the latter hearts were rejected by a mixture of humoral 
and cellular mechanisms. 
Liver allograft survival in heart-sensitized LEW re-
cipients was even more variable. Although many of the 
liver grafts were rejected before 4 days during the entire 
15 wk after sensitization, slightly enhanced graft sur-
vival was not uncommon in grafts placed after 6 wk (Fig. 
4). Grafts surviving between 3 and 7 days often showed 
a mixed humoral and cellular rejection at the time of 
failure. 
Blood Sensitization. Prior blood transfusions had 
little effect on subsequent heart allograft survival, 
although a slight but statistically insignificant prolon-
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FIG. 4. Graft survival after heart sensitization. *Median survival of 
ACI heart grafts (6 days, N = 7). **Median survival of ACI liver graft 
(10 days, N = 7) in unsensitized LEW recipient. 
significantly enhanced in all animals (p < 0.001) (Table 
2). Only one of the failed liver allografts showed classic 
cellular rejection. The others showed marked sinusoidal 
Kupffer cell hypertrophy and sinusoidal lymphohistio-
cytosis with a modest portal infiltrate. 
Cytotoxic Antibody Titers Before and After 
Graft Rejection 
When the liver grafts were rejected within 4 days of 
transplantation, a significant decrease in LAb titer was 
seen in both skin-sensitized and heart-sensitized an-
imals (Fig. 5). Antibody titers fell less dramatically after 
heart transplantation. 
When the liver and heart grafts were rejected after 4 
days, significant falls in antibody titers were not ob-
served, and in fact an increase in titer was observed in 
some. 
DISCUSSION 
Our results suggest that at least three variables 
influence the results obtained with transplantation in 
sensitized recipients: the type of organ allograft, the 
organ used for sensitization and the time elapsed after 
priming. The repetitiveness of priming is likely a fourth 
factor. Consistent with prior observations (3-10, 16, 17) 
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FIG. 5. Cytotoxic antibody titer before and after heart or liver transplantation. Heart Tx = heart transplantation; liver Tx = liver 
transplantation; before Tx = titers before heart or liver transplantation; after Tx = titers after heart or liver transplantation; < 4 days = grafts 
rejected within 4 days; ;;;0, 4 days = grafts survived for 4 or more days. 
TABLE 2. Graft survival after whole-blood sensitization compared with unsensitized LEW controls 
Sensitization N Survival time (days) MST p Value 
Heart graft survival 
Control 7 6, 6, 6, 6, 6, 7, 7 6.0 
Whole blood 6 6,6,7,7,8,9 7.0 NS 
Liver graft survival 
Control 10 9, 9, 9, 9, 10, 10, 10, 11, 12, 13 10.0 
Whole blood 6 18, 19, 21, 22, 78, 79 21.5 <0.001 
MST = median survival time (days). 
p values VB. control (Mann-Whitney U test). 
liver grafts were more resistant to antibody-mediated 
damage than cardiac grafts. The dual hepatic vascu-
1ature' secretion of soluble major histocompatibility 
complex antigens and the protective activity of Kupffer 
cells, which clear immune complexes, platelet aggregates 
and activated coagulation proteins, may contribute to 
hepatic resistance (16-19). 
However, our studies and earlier reports show that 
the liver's immunological privilege is only relative (4-8). 
In earlier reports of experimental liver transplantation 
in rats (6) and primates (5), no association was seen 
between the antibody titers and the outcome. Our data 
provide this sought-after association that others have 
claimed for cardiac grafts (20, 21). The clinical impli-
cation for liver transplantation is that determination of 
cytotoxic antibody titers may be equal in importance or 
more so than the presence of a positive crossmatch. In 
clinical practice it is uncommon to have titers greater 
than 1: 512, whereas this was the usual condition in our 
sensitized animals. Therefore determination of antibody 
titer pretransplantation may increase the predictive 
value of the crossmatch test. 
An additional reservation about conventional clinical 
crossmatch procedures is that the recipient antibody 
state is dynamic rather than fixed. The LAb titer may be 
affected by antibody class, specificity and antiidiotype 
antibodies (22), which change with time. The quality of 
these changes apart from quantitative reduction of 
antibody levels is under investigation. Such studies are 
needed because it is clear that the LAb titer alone does 
not sufficiently explain the results obtained with dif-
ferent methods of sensitization. Similar high titers of 
preformed LAb were observed in some animals who 
subsequently hyperacutely rejected their grafts and in 
others who experienced enhancement. 
Until now, the best clue to explain such disparate 
results has come from indirect immunofluorescent 
analysis, which showed differences in target antigen 
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specificity in the liver, depending on the method of 
sensitization. Sensitization with skin protocol produced 
a subfraction of IgG antibodies with specificity for the 
hepatic vascular endothelium, and this appeared to be 
associated with accelerated graft failure. Such an obser-
vation is in accord with most clinical studies in which 
IgG antibodies (in contrast to IgM) with endothelial cell 
specificity have seemed to be the most dangerous (4, 7, 
23-27). 
Blood transfusions also produced LAb but with ap-
preciably less hepatic endothelial specificity and with the 
consequence of frequent enhancement of hepatic graft 
survival. Thus the lymphocytotoxic crossmatch is only a 
surrogate test for graft-reactive antibodies. Further or 
different characterization of preformed antibody may be 
needed to predict the outcome in sensitized liver al-
lograft recipients. 
To our knowledge, this is the first demonstration that 
liver grafts are enhanced with blood transfusions. 
Enhancement was first observed in kidney transplan-
tation after blood transfusion (28, 29). Numerous 
experimental and clinical studies have been performed 
in an attempt to unravel underlying mechanisms 
(30-38). Our experiments do not add to the earlier 
hypothesis beyond the demonstration of the ease of 
hepatic graft enhancement relative to that of heart 
grafts. 
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